|
99 Companies |
|
136 Products |
|
136 Products |
|
121 Mechanisms of Action |
|
5 Trials |
|
1112 News |
|
| «12345678910111213...1617» |
- | Trial completion, Enrollment change, Trial initiation date, Trial primary completion date, Surgery: Fibrin Glue vs. Suture in Pterygium Surgery (clinicaltrials.gov) - Aug 8, 2017
P=N/A, N=90, Completed, Sponsor: Dr. Guy Ben-Simon, MD
Recruiting --> Completed | N=60 --> 90 | Initiation date: Jan 2010 --> Jan 2014 | Trial primary completion date: Dec 2016 --> May 2016
- || Dificid (fidaxomicin) / Merck (MSD), Astellas
Enrollment closed: DAFNE: Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients (clinicaltrials.gov) - Jul 26, 2017
P=N/A, N=297, Active, not recruiting, Sponsor: Astellas Pharma S.A.S.
Recruiting --> Completed | N=60 --> 90 | Initiation date: Jan 2010 --> Jan 2014 | Trial primary completion date: Dec 2016 --> May 2016 Recruiting --> Active, not recruiting
- | Avastin (bevacizumab) / Roche
Enrollment change, Trial termination, Trial primary completion date: Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence (clinicaltrials.gov) - Jul 12, 2017
P1, N=1, Terminated, Sponsor: Brain & Spine Surgeons of New York
Recruiting --> Active, not recruiting N=24 --> 1 | Recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Jan 2012; Investigators decision
- | Trial completion: Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients (clinicaltrials.gov) - Jul 6, 2017
P3, N=164, Completed, Sponsor: Mukoviszidose Institut gGmbH
N=24 --> 1 | Recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Jan 2012; Investigators decision Active, not recruiting --> Completed
- | Trial completion: A Prospective Randomized Study Evaluating the Recurrence Rate of Chronic Subdural Hematoma After Placing a Subperiosteal Drainage Compared to a Subdural Drainage (clinicaltrials.gov) - Jun 27, 2017
P=N/A, N=220, Completed, Sponsor: Kantonsspital Aarau
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Votrient (pazopanib) / Novartis, BeiGene
Biomarker, Trial completion, Trial primary completion date: Neoadjuvant Pazopanib in Renal Cell Carcinoma (clinicaltrials.gov) - Jun 14, 2017
P2, N=21, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jan 2015 | Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jan 2015
- | Trial completion, Phase classification, Trial primary completion date: Ga-68-NODAGA-MJ9 Compared to F-18-FCH PET/CT for Prostate Cancer Patients (clinicaltrials.gov) - May 23, 2017
P=N/A, N=60, Completed, Sponsor: University of Lausanne Hospitals
Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jan 2015 | Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jan 2015 Recruiting --> Completed | Phase classification: P1/2 --> PN/A | Trial primary completion date: Mar 2017 --> Oct 2016
- | Phase classification: New Therapy of Laryngeal Papilloma In Children (clinicaltrials.gov) - May 18, 2017
P=N/A, N=1, Terminated, Sponsor: Boston University
Recruiting --> Completed | Phase classification: P1/2 --> PN/A | Trial primary completion date: Mar 2017 --> Oct 2016 Phase classification: P2 --> P=N/A
- | Trial completion, Trial initiation date, Trial primary completion date: E2197T2: Studying Tumor Samples From Women Who Have Undergone Chemotherapy for Breast Cancer (clinicaltrials.gov) - May 17, 2017
P=N/A, N=2541, Completed, Sponsor: ECOG-ACRIN Cancer Research Group
Phase classification: P2 --> P=N/A Not yet recruiting --> Completed | Initiation date: Jan 2009 --> Jun 2008 | Trial primary completion date: Jul 2011 --> Dec 2013
- | Trial completion, Trial primary completion date: REMARK: Pro-coagulant Markers and Anticoagulant Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism (clinicaltrials.gov) - May 11, 2017
P=N/A, N=700, Completed, Sponsor: Ottawa Hospital Research Institute
Not yet recruiting --> Completed | Initiation date: Jan 2009 --> Jun 2008 | Trial primary completion date: Jul 2011 --> Dec 2013 Trial primary completion date: Jun 2015 --> Oct 2016 | Active, not recruiting --> Completed
- | Trial completion: Usefulness of Ki67 Index in Hormone Receptor-positive Breast Cancer (clinicaltrials.gov) - May 1, 2017
P=N/A, N=1070, Completed, Sponsor: Samsung Medical Center
Trial primary completion date: Jun 2015 --> Oct 2016 | Active, not recruiting --> Completed Active, not recruiting --> Completed
- | lamivudine HBV / Generic mfg., lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
Enrollment change, Trial termination: A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 28, 2017
P3, N=117, Terminated, Sponsor: National Health Research Institutes, Taiwan
Active, not recruiting --> Completed N=309 --> 117 | Active, not recruiting --> Terminated; No cases enrollment
- | Trial completion: Sulforaphane in Treating Patients With Recurrent Prostate Cancer (clinicaltrials.gov) - Apr 28, 2017
P2, N=20, Completed, Sponsor: OHSU Knight Cancer Institute
N=309 --> 117 | Active, not recruiting --> Terminated; No cases enrollment Active, not recruiting --> Completed
- | Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Enrollment change, Trial withdrawal: Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients (clinicaltrials.gov) - Apr 25, 2017
P3, N=0, Withdrawn, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed N=56 --> 0 | Recruiting --> Withdrawn
- | Trial completion, Enrollment change, Trial primary completion date: Clinical Benefits of Additional Complex Fractionated Atrial Electrogram Targeted Catheter Ablation for Longstanding Persistent Atrial Fibrillation (clinicaltrials.gov) - Apr 25, 2017
P=N/A, N=40, Completed, Sponsor: Yonsei University
N=56 --> 0 | Recruiting --> Withdrawn Recruiting --> Completed | N=220 --> 40 | Trial primary completion date: Jun 2024 --> Feb 2017
- | Trial primary completion date, Surgery: Breast Cancer With Low Risk Of Local Recurrence: Partial and Accelerated Radiation With Three-Dimensional Conformal Radiotherapy (3DCRT) Vs. Standard Radiotherapy After Conserving Surgery (Phase III Study (clinicaltrials.gov) - Apr 25, 2017
P3, N=3302, Recruiting, Sponsor: Regione Emilia-Romagna
Recruiting --> Completed | N=220 --> 40 | Trial primary completion date: Jun 2024 --> Feb 2017 Trial primary completion date: Dec 2015 --> Jun 2018
- | selenomethionine (SLM) / University of Iowa, Holden Comprehensive Cancer Center
Trial initiation date: Herbal Therapy for Treatment of Recurrent Prostate Cancer (clinicaltrials.gov) - Apr 20, 2017
P2, N=43, Completed, Sponsor: University of Southern California
Trial primary completion date: Dec 2015 --> Jun 2018 Initiation date: Nov 2008 --> Jul 2008
- | Trial completion, Enrollment change, Trial primary completion date: Modified "Open Intraperitoneal Mesh" Technique of Incisional Ventral Hernia Repair (clinicaltrials.gov) - Apr 19, 2017
P=N/A, N=124, Completed, Sponsor: Varazdin General Hospital
Initiation date: Nov 2008 --> Jul 2008 Recruiting --> Completed | N=100 --> 124 | Trial primary completion date: Sep 2014 --> May 2014
- | Betadine (povidone iodine) / Egis
Trial termination, Trial primary completion date, Surgery: A Randomised Study to Assess Betadine in the Groin Wound of Patients Undergoing Primary Varicose Vein Surgery (clinicaltrials.gov) - Apr 12, 2017
P3, N=60, Terminated, Sponsor: Royal Hobart Hospital
Recruiting --> Completed | N=100 --> 124 | Trial primary completion date: Sep 2014 --> May 2014 Recruiting --> Terminated | Trial primary completion date: Dec 2010 --> Dec 2013; Recruitement too slow
- | Trial primary completion date: Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients (clinicaltrials.gov) - Mar 23, 2017
P3, N=164, Active, not recruiting, Sponsor: Mukoviszidose Institut gGmbH
Recruiting --> Terminated | Trial primary completion date: Dec 2010 --> Dec 2013; Recruitement too slow Trial primary completion date: Dec 2016 --> Jun 2017
- ||| Trial completion, Enrollment change: THORN: Ability of Home Monitoring® to Detect and Manage the Inappropriate Diagnoses in Implantable Cardioverter Defibrillators. (clinicaltrials.gov) - Mar 17, 2017
P=N/A, N=512, Completed, Sponsor: Biotronik SE & Co. KG
Trial primary completion date: Dec 2016 --> Jun 2017 Active, not recruiting --> Completed | N=1750 --> 512
- || imatinib / Generic mfg.
Trial primary completion date, Stroma: Five Year Adjuvant Imatinib Mesylate (Gleevec (clinicaltrials.gov) - Mar 1, 2017
P2, N=91, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | N=1750 --> 512 Trial primary completion date: May 2018 --> Apr 2017
- ||||||| NeuVax (nelipepimut-S) / Dr. Reddy's
Trial completion, Trial primary completion date: PRESENT: Efficacy and Safety Study of NeuVax (clinicaltrials.gov) - Feb 24, 2017
P3, N=700, Completed, Sponsor: Galena Biopharma, Inc.
Trial primary completion date: May 2018 --> Apr 2017 Active, not recruiting --> Completed | Trial primary completion date: Apr 2018 --> Sep 2016
- | Trial primary completion date: PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma (clinicaltrials.gov) - Feb 23, 2017
P2, N=1500, Recruiting, Sponsor: Phoenix Molecular Imaging
Active, not recruiting --> Completed | Trial primary completion date: Apr 2018 --> Sep 2016 Trial primary completion date: Apr 2017 --> Apr 2018
- | morphine sulphate / Generic mfg.
Trial primary completion date, Surgery, Minimal residual disease: Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery (clinicaltrials.gov) - Feb 23, 2017
P4, N=60, Recruiting, Sponsor: The Institute of Molecular and Translational Medicine, Czech Republic
Trial primary completion date: Apr 2017 --> Apr 2018 Trial primary completion date: Oct 2017 --> May 2018
- | budesonide inhalation suspension / Generic mfg.
Trial completion, Enrollment change: Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial (clinicaltrials.gov) - Feb 17, 2017
P1, N=36, Completed, Sponsor: Vanderbilt University
Trial primary completion date: Oct 2017 --> May 2018 Active, not recruiting --> Completed | N=30 --> 36
- Ilaris (canakinumab) / Novartis
Enrollment change, Trial primary completion date: Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF (clinicaltrials.gov) - Feb 14, 2017
P2, N=24, Terminated, Sponsor: University Hospital, Basel, Switzerland
Active, not recruiting --> Completed | N=30 --> 36 N=30 --> 24 | Trial primary completion date: Sep 2016 --> Dec 2016
- Trial completion, Phase classification: TOSCAN: To Scan or Not to Scan: The Role of Follow-up CT Scanning for Management of Chronic Subdural Hematoma After Neurosurgical Evacuation (clinicaltrials.gov) - Feb 13, 2017
P=N/A, N=368, Completed, Sponsor: University Hospital Inselspital, Berne
N=30 --> 24 | Trial primary completion date: Sep 2016 --> Dec 2016 Recruiting --> Completed | Phase classification: P3 --> PN/A
- Trial completion, Enrollment change: Optimizing Postpartum Contraception in Women With Preterm Births (clinicaltrials.gov) - Feb 6, 2017
P=N/A, N=134, Completed, Sponsor: University of Utah
Recruiting --> Completed | Phase classification: P3 --> PN/A Active, not recruiting --> Completed | N=362 --> 134
- | imatinib / Generic mfg.
Phase classification, Stroma: Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) (clinicaltrials.gov) - Feb 6, 2017
P2, N=132, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | N=362 --> 134 Phase classification: P4 --> P2
- Trial completion: ROTEA: Safety Monitoring of Patients Having Pulmonary Vein Ablation (clinicaltrials.gov) - Feb 3, 2017
P=N/A, N=42, Completed, Sponsor: The Cleveland Clinic
Phase classification: P4 --> P2 Recruiting --> Completed
- | Trial completion: CLOSE: Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence (clinicaltrials.gov) - Feb 3, 2017
P3, N=664, Completed, Sponsor: Assistance Publique - H
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Tuberculosis Recurrence Upon Treatment With Highly Active Antiretroviral Therapy (clinicaltrials.gov) - Feb 2, 2017
P=N/A, N=402, Completed, Sponsor: Centre for the AIDS Programme of Research in South Africa
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Apr 2014
- Ilaris (canakinumab) / Novartis
Enrollment change, Trial termination, Trial primary completion date: Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF (clinicaltrials.gov) - Feb 1, 2017
P2, N=30, Terminated, Sponsor: University Hospital, Basel, Switzerland
Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Apr 2014 N=100 --> 30 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Sep 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer (clinicaltrials.gov) - Jan 30, 2017
P1/2, N=17, Terminated, Sponsor: Boneca Corporation
N=100 --> 30 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Sep 2016 Trial primary completion date: Dec 2013 --> Jun 2013
- Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Phase classification, Enrollment change, Trial withdrawal: Cesium-131 Seed Brachytherapy Plus Subtotal Resection for Lung Cancer Patients (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=0, Withdrawn, Sponsor: Weill Medical College of Cornell University
Trial primary completion date: Dec 2013 --> Jun 2013 Phase classification: P4 --> P=N/A | N=40 --> 0 | Recruiting --> Withdrawn
- | Enrollment closed, Enrollment change: iTEPsein: ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA (clinicaltrials.gov) - Jan 19, 2017
P1/2, N=23, Active, not recruiting, Sponsor: Nantes University Hospital
Phase classification: P4 --> P=N/A | N=40 --> 0 | Recruiting --> Withdrawn Recruiting --> Active, not recruiting | N=60 --> 23
- | Trial completion, Trial primary completion date: The Value of Bacterial Loads by Real Time PCR in Predicting Recurrence of Abnormal Vaginal Flora After Oral Metronidazole Therapy (clinicaltrials.gov) - Jan 13, 2017
P3, N=182, Completed, Sponsor: Assistance Publique Hopitaux De Marseille
Recruiting --> Active, not recruiting | N=60 --> 23 Recruiting --> Completed | Trial primary completion date: Jan 2015 --> Jan 2016
- Trial primary completion date: TOSCAN: To Scan or Not to Scan: The Role of Follow-up CT Scanning for Management of Chronic Subdural Hematoma After Neurosurgical Evacuation (clinicaltrials.gov) - Jan 12, 2017
P3, N=400, Recruiting, Sponsor: University Hospital Inselspital, Berne
Recruiting --> Completed | Trial primary completion date: Jan 2015 --> Jan 2016 Trial primary completion date: Jul 2017 --> Feb 2017
- rivaroxaban / Generic mfg.
Trial completion: Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer (clinicaltrials.gov) - Jan 9, 2017
P4, N=127, Completed, Sponsor: Seoul National University Hospital
Trial primary completion date: Jul 2017 --> Feb 2017 Active, not recruiting --> Completed
- ||| Trial completion, Metastases: Non-Interventional Study PREVENT (clinicaltrials.gov) - Dec 28, 2016
P=N/A, N=200, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Surgery: Laparoscopic Sentinel Node Navigation Surgery for Gastric Cancer (clinicaltrials.gov) - Dec 21, 2016
P2, N=100, Completed, Sponsor: Seoul National University Bundang Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: PET-MRI After Radiofrequency Ablation (RFA) or Microwave Ablation (MWA) (clinicaltrials.gov) - Dec 15, 2016
P=N/A, N=20, Completed, Sponsor: dr. M.P. van den Tol MD PhD
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jan 2015 --> Jun 2016
- vancomycin / Generic mfg.
Enrollment change: Extended Treatment With Vancomycin for Clostridium Difficile Colitis (clinicaltrials.gov) - Dec 14, 2016
P=N/A, N=0, Withdrawn, Sponsor: William Beaumont Hospitals
Recruiting --> Completed | Trial primary completion date: Jan 2015 --> Jun 2016 N=50 --> 0
- Biomarker, Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Markers of Response to Intravesical Bladder Cancer Therapy (clinicaltrials.gov) - Dec 7, 2016
P=N/A, N=150, Completed, Sponsor: M.D. Anderson Cancer Center
N=50 --> 0 Active, not recruiting --> Completed | N=300 --> 150 | Initiation date: Aug 2009 --> Jun 2005 | Trial primary completion date: Aug 2017 --> Apr 2016
- || Trial primary completion date: Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy (clinicaltrials.gov) - Dec 2, 2016
P4, N=1080, Active, not recruiting, Sponsor: Qidong Gaitianli Medicines Co., Ltd
Active, not recruiting --> Completed | N=300 --> 150 | Initiation date: Aug 2009 --> Jun 2005 | Trial primary completion date: Aug 2017 --> Apr 2016 Trial primary completion date: Jun 2016 --> Dec 2016
- Trial completion, MRI: Magnetic Resonance Imaging of Mesh Position After Ventral Hernia Repair (clinicaltrials.gov) - Nov 25, 2016
P=N/A, N=15, Completed, Sponsor: Algemeen Ziekenhuis Maria Middelares
Trial primary completion date: Jun 2016 --> Dec 2016 Active, not recruiting --> Completed
- | escitalopram / Generic mfg.
Trial completion, Head-to-Head: Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial (clinicaltrials.gov) - Nov 23, 2016
P3, N=245, Completed, Sponsor: University of Sao Paulo
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Polypropylene Mesh Versus Polytetrafluoroethylene (PTFE) Mesh in Inguinal Hernia Repair (clinicaltrials.gov) - Nov 22, 2016
P4, N=70, Completed, Sponsor: University of Roma La Sapienza
Active, not recruiting --> Completed Active, not recruiting --> Completed
- paclitaxel / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: Reirradiation With Concurrent Paclitaxel for Breast Cancer (clinicaltrials.gov) - Nov 15, 2016
P1, N=0, Withdrawn, Sponsor: University of Kentucky
Active, not recruiting --> Completed N=18 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Mar 2018 --> Dec 2015